Physician Assistant · Auburn, NY
NPI
1043826282
Since 2020
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
144 Standart Ave
Auburn, NY, 13021
Phone (315) 255-1100
Groups this clinician bills Medicare through
Medicare paid, 2024
$124K
2,681 services
Medicare patients, 2024
503
Average age 71
Drug cost, 2024
$2.5M
1,673 prescriptions
Company payments, 2025
$8,165
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alex J Zwierzynski was code 17003 (destruction skin lesion), 570 times for 132 patients. In total Alex J Zwierzynski billed 2,681 services in 52 codes, and Medicare paid $124K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 570 | 132 | $3.78 | $2,155 |
| 99213 Office E&M - Established | Office | 492 | 386 | $49.76 | $24K |
| 17000 Destruction Skin Lesion | Office | 213 | 172 | $34.66 | $7,382 |
| 99214 Office E&M - Established | Office | 62 | 41 | $69.26 | $4,294 |
| 11102 Skin Biopsy | Office | 51 | 47 | $59.18 | $3,018 |
| 99203 Office E&M - New | Office | 49 | 49 | $59.53 | $2,917 |
| 99212 Office E&M - Established | Office | 36 | 35 | $33.49 | $1,206 |
| 17110 Destruction Skin Lesion | Office | 27 | 17 | $63.43 | $1,713 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 16 | 14 | $8.57 | $137 |
| 99202 Office E&M - New | Office | 15 | 15 | $30.90 | $464 |
By year: 2022 $167K for 2,826 services; 2023 $131K for 2,671 services; 2024 $124K for 2,681 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alex J Zwierzynski prescribed most often to Medicare patients was Triamcinolone Acetonide, with 144 prescriptions and refills. In total Alex J Zwierzynski wrote 1,673 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 144 | 171 | 79 | $1,522 |
| Ketoconazole Generic | 121 | 129 | 51 | $2,437 |
| Dupixent Pen Dupilumab | 103 | 105 | 12 | $389K |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 88 | 89 | 44 | $1,689 |
| Tacrolimus Generic | 87 | 99 | 46 | $11K |
| Hydrocortisone Generic | 71 | 71 | 22 | $252 |
| Spironolactone Generic | 71 | 94 | Under 11 | $998 |
| Mupirocin Generic | 63 | 68 | 31 | $1,064 |
| Doxycycline Hyclate Generic | 55 | 93 | 23 | $2,172 |
| Imiquimod Generic | 49 | 50 | 36 | $1,860 |
| Metronidazole Generic | 45 | 53 | 23 | $1,867 |
| Clobetasol Propionate Generic | 37 | 38 | 15 | $2,187 |
| Prednisone Generic | 35 | 41 | 28 | $92.97 |
| Hydroxyzine Hcl Generic | 34 | 57 | 13 | $322 |
| Ciclopirox Generic | 34 | 34 | Under 11 | $1,904 |
Brand drugs: 371 claims; generic drugs: 1,302 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alex J Zwierzynski $8,165 ($8,165 in general payments such as food, travel and fees) from 20 companies. The largest payer was Lilly USA, LLC with $3,592.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 16 | $3,592 |
| Abbvie Inc. ABBV | 46 | $850 |
| Janssen Biotech, Inc. JNJ | 31 | $627 |
| LEO Pharma Inc. | 18 | $437 |
| Incyte Corporation INCY | 27 | $431 |
| UCB, Inc. UCB.BR | 28 | $410 |
| Novartis Pharmaceuticals Corporation NVS | 24 | $383 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 16 | $293 |
| E.R. Squibb & Sons, L.L.C. BMY | 16 | $222 |
| Regeneron Healthcare Solutions, Inc. REGN | 11 | $211 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.